Showing 1291-1300 of 5771 results for "".
- EyeCool Therapeutics Announces Positive Results from Pilot Study in Patients with Chronic Ocular Surface Pain (COSP)https://modernod.com/news/eyecool-therapeutics-announces-positive-results-from-pilot-study-in-patients-with-chronic-ocular-surface-pain-cosp/2482799/EyeCool Therapeutics announced positive clinical data from a double-masked, randomized controlled pilot study of 31 patients in Australia evaluating the safety and efficacy of its investigational device (ETX-4143) for the treatment of Chronic Ocular Surface Pain (COSP). T
- Perfuse Therapeutics Announces Positive Results from Phase 1/2a Trial of PER-001 Intravitreal Implant in Patients with Glaucomahttps://modernod.com/news/perfuse-therapeutics-announces-positive-results-from-phase-12a-trial-of-per-001-intravitreal-implant-in-patients-with-glaucoma/2482794/Perfuse Therapeutics announced positive 24-week results from its completed phase 1/2a trial of PER-001, a first in class endothelin antagonist intravitreal implant for glaucoma. Steven Mansberger, MD, MPH, Chief of Ophthalmology and Director of Gl
- Versea Ophthalmics Announces Novel Application of Biovance Product Portfolio in Retinal Procedureshttps://modernod.com/news/versea-ophthalmics-announces-novel-application-of-biovance-product-portfolio-in-retinal-procedures/2482787/Verséa Ophthalmics has announced that results from recent application of Biovance and Biovance 3L Ocular products in macular hole repair will be presented at the upcoming Retinal World Congress (RWC) being held from May 8-11, 2025 in Fort Lauderdale, FL. The macula
- Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVOhttps://modernod.com/news/opus-genetics-announces-presentation-of-opgx-lca5-gene-therapy-data-at-arvo/2482782/Opus Genetics announced 1-year results from adult patients treated in the ongoing phase 1/2 Study of its lead gene therapy candidate OPGx-LCA5. These results were presented at the 2025 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), taking place May 4
- Chengdu Origen and Vanotech Announce First Patient Dosed in Phase 1 Trial of Gene Therapy for Wet AMDhttps://modernod.com/news/chengdu-origen-and-vanotech-announce-first-patient-dosed-in-phase-1-trial-of-gene-therapy-for-wet-amd/2482781/Chengdu Origen Biotechnology and Vanotech announced that the first patient dosed in the VAN-2401 multicenter phase 1 clinical trial evaluating treatment with KH658 for patients with wet age-related macular degeneration (AMD). This multicenter, open-lab
- Sydnexis Announces Three Abstracts Accepted for Poster Presentations at ARVOhttps://modernod.com/news/sydnexis-announces-three-abstracts-accepted-for-poster-presentations-at-arvo/2482780/Sydnexis announced that three abstracts have been accepted for poster presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2025 meeting taking place from May 4 to 8 in Salt Lake City. These posters present clinical data related to the STAR Study
- 4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DMEhttps://modernod.com/news/4dmt-announces-rmat-designation-granted-by-fda-for-4d-150-for-dme/2482776/4D Molecular Therapeutics announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to 4D-150 for the treatment of diabetic macular edema (DME). RMAT designation is part of the 21st Century Cures Act and was created to expedite the developmen
- Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresseshttps://modernod.com/news/astellas-to-present-new-data-in-geographic-atrophy-at-upcoming-ophthalmology-annual-congresses/2482775/Astellas Pharma will highlight new data that enhances continued understanding of the science of geographic atrophy (GA), and the experience of patients living with the progressive disease at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO), May 4-8, Salt Lake City, U
- RetinAI and FVS Announce CE-MDR Certification for Co-Developed AI-Based DR Screening Algorithm, LuxIAhttps://modernod.com/news/retinai-and-fvs-announce-ce-mdr-certification-for-co-developed-ai-based-dr-screening-algorithm-luxia/2482773/RetinAI US and Fundación Ver Salud (FVS) have jointly announced that LuxIA, their co-developed AI algorithm for diabetic retinopathy (DR) screening, has successfully received CE-MDR certification as a Class IIb medical device under the European
- iStar Medical Announces Positive 5-year Results of MINIject® in Glaucoma Patientshttps://modernod.com/news/istar-medical-announces-positive-5-year-results-of-miniject-in-glaucoma-patients/2482760/iStar Medical has announced positive 5-year results from the STAR-GLOBAL trial for their MINIject®device in patients with open-angle glaucoma. STAR-GLOBAL is an extension trial investigating the long-term safety and efficacy of MINIject® up to five years after im